期刊论文详细信息
Pharmacology Research & Perspectives | |
CCN5 activation by free or encapsulated EGCG is required to render triple‐negative breast cancer cell viability and tumor progression | |
Amlan Das1  Indranil Chatterjee1  Archana De1  Inamul Haque1  Snigdha Banerjee2  Arnab Ghosh2  Sushanta K. Banerjee3  Priyanka Ray4  Mohiuddin Quadir5  Debasmita Dutta5  Sumedha Gunewardena6  Scott Weir7  | |
[1] Cancer Research Unit, VA Medical Center, Kansas City, MO, USA;Cancer Research Unit, VA Medical Center, Kansas City, MO, USA;Department of Pathology and Laboratory Medicine, University of Kansas Medical Center, Kansas City, KS, USA;Cancer Research Unit, VA Medical Center, Kansas City, MO, USA;Department of Pathology and Laboratory Medicine, University of Kansas Medical Center, Kansas City, KS, USA;Lead contact, SKB, Cancer Research Unit, Kansas City, MO, USA;Department of Chemical Biochemical Environmental Engineering (CBEE, University of Maryland, Baltimore, MD, USA;Department of Coatings and Polymeric Materials, North Dakota State University, Fargo, ND, USA;Department of Molecular and Integrative Physiology, University of Kansas Medical Center, Kansas City, KS, USA;Department of Pharmacology, Toxicology and Therapeutics, University of Kansas Medical Center, Kansas City, KS, USA; | |
关键词: bioavailability; breast cancer; CCN5; drug delivery; EGCG; FA‐PEG‐NPs; folic acid; nanoparticles; PCNA; TNBC; | |
DOI : 10.1002/prp2.753 | |
来源: Wiley | |